⏳ Final countdown: 2 weeks to #BavenoVIII‼️ 9⃣ expert panels across the full PH spectrum 📍 Baveno, Italy 🌐 Hybrid format — join in person or online 🔗 baveno8.org/registration Don’t miss it! Programme 👇

⏳ Final countdown: 3 weeks to #BavenoVIII‼️ 9⃣ expert panels across the full PH spectrum — from risk stratification in cACLD to decompensation prevention/management, bleeding, recompensation & vascular liver disorders 🗓️ 27-28 March-🧒29/03 🔗 baveno8.org 📄 Programme👇

⌛️4 weeks to #BavenoVIII‼️ 9⃣ expert panels covering the full spectrum of PH — from risk stratification in cACLD & fibrosis modifiers to decompensation prevention & management, bleeding, recompensation, and vascular liver disorders 🔗https://baveno8.org Programme 👇

Scientific progress moves forward because others laid the foundations @BavenoCoop is no exception ⏳ 5 weeks to #BavenoVIII (baveno8.org) As we prepare, we remember the legends of portal hypertension who are no longer with us 🧵

6⃣ weeks to #BavenoVIII -> baveno8.org It´s time to revisit the mission of @BavenoCoop ❓What is it — An official EASL consortium setting global standards for the management of ACLD, with a special focus on portal hypertension ❓How did it start — Follow🧵

🇨🇦 Are you a young @CASLupdates member ⁉️ 🇮🇹Do you want to attend #BavenoVIII (Mar 27–28, 2026) ?👇 💰 $2,500 CAD travel grant 🎙️ CASL webinar after the meeting 🔎 Open to young CASL members ⏰ DEADLINE: February 15 - ONLY 9 DAYS LEFT‼️ 👉 Apply here: hepatology.ca/baveno-conse...

🚨Liver lovers alert -> Just 7 weeks to go for #BavenoVIII ‼️ 🗓️ 27–28 March 2026 (👶 Pediatric Symposium: 29 March) 📍 Baveno, Italy 🌐 Hybrid format — join in person or online 🔗 baveno8.org/registration Don’t miss it! Programme 👇

🙏 Your prayers have been heard! The abstract submission deadline for the VIII Baveno Consensus Workshop has been extended 🎉 ⏰ New deadline: 22 January 2026 — one week left! 📅 March 27–28, 2026 (👶 March 29) 🏆 Awards & presentation opportunities 🔗 baveno8.org/abstracts/

⌛️ Only 3 days left ‼️Submit your abstract for the VIII Baveno Consensus Workshop 📅 March 27–28, 2026 (👶 March 29) 🗓️ Deadline: January 15, 2026 📍 Baveno, Italy | 🌐 Hybrid (in person & online) 🏆 Prestigious awards available 🔗 baveno8.org/abstracts/ 👇

⌛️ Only 1 week left ‼️ Submit your abstract for the VIII Baveno Consensus Workshop -March 27–28, 2026 (👶 March 29) 🗓️ Deadline: January 15, 2026 📍 Baveno, Italy | 🌐 Hybrid (in person & online) 🏆 Prestigious awards available 🔗 baveno8.org/abstracts/ 👇

🎄✨ Baveno VIII wishes you a Merry Christmas and happy holidays! 🎁 Give yourself a Christmas gift: register for #BavenoVIII‼️ 🗓️ 27–28 March 2026 (👶 29 March) 📍 Baveno, Italy 🌐 Hybrid format — in person or online 🔗 baveno8.org/registration 👇

LAST DAY‼️ 🚨 Early-bird registration for #BavenoVIII closes TODAY (15 Dec)‼️ 🗓️ 27–28 March 2026 (👶 29 March) 📍 Baveno, Italy 🌐 Hybrid format — in person or online 🧠 Abstract submissions open until Jan 15 🔗 baveno8.org/registration 👇

⏳ Who warns you isn’t a traitor... Only 4 days left‼️ Early-bird registration for Baveno VIII closes on 15 Dec‼️ 🗓️ 27–28 March 2026 (👶 29 March) 📍 Baveno, Italy 🌐 Hybrid format — in person or online 🧠 Abstract submissions open until Jan 15 🔗 baveno8.org/registration 👇

⏳ December countdown for Early-bird registration is on‼️ It ends 15 Dec‼️ Key info: 🗓️ 27–28 March 2026 (👶 Pediatric Symposium: 29 March) 📍 Baveno, Italy 🌐 Hybrid format — in person or online 🧠 Abstract submissions open until Jan 15! 🔗 baveno8.org/registration More 👇

🚨 Today is the day, folks‼️ VALDIG PSVD Meeting 2025 in Paris 🇫🇷 It’s time to watch and learn from the best. 📘 Programme below 👇

📢First BavenoVIII deadline approaching ->Early bird registration ends 15 Dec 2025‼️ Key info: 🗓️ 27–28 March 2026 (👶 Pediatric Symposium: 29 March) 📍 Baveno, Italy 🌐 Hybrid format — in person or online 🧠 Abstracts opened until Jan 15! 🔗 baveno8.org/registration More👇

🚨Just 10 days away ‼️ Join the VALDIG PSVD Meeting 2025 in Paris 🗓️ Dec 4–5 @ CNAM 💶 Onsite €150 | 💻 Online FREE 👉 Organized by EURO-VALDIG NET & FILFOIE 🔗 Registration → app.evalandgo.com/f/325218/4qE... Updated program below 👇

🆕CPG in press❕ EASL Clinical Practice Guidelines on vascular diseases of the liver Find it here👉https://www.journal-of-hepatology.eu/article/S0168-8278(25)02406-7/fulltext #LiverSky @easlnews.bsky.social

🚨Just 3 weeks away‼️ Join the VALDIG PSVD Meeting 2025 in Paris 🇫🇷 🗓️ Dec 4–5 @ CNAM 💳 Onsite €150 | 💻 Online FREE 👉 Organized by EURO-VALDIG NET & FILFOIE 🔗 Registration → app.evalandgo.com/f/325218/4qE... 📘 Updated program below 👇 #LiverTwitter

And if you look after adult patients with #MASLD, here is a cue on how to approach treatment 👇 #TLM25 #LiverSky

How to approach #MASLD at different stages of our patients lives Fantastic summary slide from @marurinella #PostGraduateCourse #TLM25 @aasldnews.bsky.social

So excited to be in Washington DC for my first #TLM25 with wonderful colleagues! A toast to you all with a delicious mocktail! Will see you around! Can’t wait! #LiverTwitter @aasldnews.bsky.social

Recompensation take home points ⏳off all diuretics and medications for HE 📌happens in 1 out of 3 patients depending etiology 🖋️multiple factors affect it 🔎 improves survival and LR mortality 📍Risk of HCC remains the same: don’t stop screening @anahitarabiee.bsky.social #liversky #TLM25

Best practices of management of obesity in liver transplant FANTASTIC work by @drjessicadavis.bsky.social et al leading a controversy conference and consensus paper 👇🏼👇🏼👇🏼 Her beautiful graph won the cover photo 👌🏼 #liversky #TLM25 @aasldnews.bsky.social @ast-licop.bsky.social

🎬 Want to know why you should register for the VALDIG PSVD Meeting 2025 in Paris 🇫🇷? 🗓️ Dec 4–5 @ CNAM 💳 Onsite €150 | 💻 Online FREE Watch the video below and see why you can’t miss it! 🔗 Register here: app.evalandgo.com/f/325218/4qE...

🚨Just one month away‼️ Join the VALDIG PSVD Meeting 2025 in Paris 🇫🇷 🗓️ Dec 4–5 @ CNAM 💳 Onsite €150 | 💻 Online FREE 👉 Organized by EURO-VALDIG NET & FILFOIE 🔗 Registration -> app.evalandgo.com/f/325218/4qE... 📘 Full program below 👇 #LiverTwitter

In anticipation of registration for @bavenocoop.bsky.social VIII Do not miss this new publication on refining Baveno VII criteria for CSPH individual-patient data meta-analysis #liversky pubmed.ncbi.nlm.nih.gov/41138818/ @easlnews.bsky.social

Loss of Bile Salt Export Pump (Bsep/Abcb11) Ameliorates Toxin-induced Hepatic Fibrosis via Suppression of Hepatocellular Jun Amino-terminal Kinase Signaling and Hepatic Stellate Cell Activation - Cellular and Molecular Gastroenterology and Hepatology www.cmghjournal.org/article/S235...

⏳ Just 5 months left for #BavenoVIII! 🗓️ 27-28 March 2026 (👶 Pediatric Symposium: 29 March) 📍 Baveno, Italy 🌐 The event will take place in a hybrid formula — both in person and online. 🧠 Call for abstracts is now open! 🔗 More info at: baveno8.org 🧵

#Liver #Cirrhosis #PortalHypertension A recent @meduniwien.ac.at study investigated #cirrhosis pts with variceal bleeding over two 🕐 🕕 🕘 decades: ✅ decreasing rebleeding🩸rates ✅ lower bleeding-related ☠️ mortality in the more recent decade ☺️ 📕 GIE Endoscopy 🔗 www.giejournal.org/article/S001...

🔬 Passionate about vascular liver diseases? Join the VALDIG PSVD Meeting 2025 in Paris 🇫🇷! 🗓️ Dec 4–5 @ CNAM 💳 Onsite €150 | 💻 Online free 👉 Organized by EURO-VALDIG NET & FILFOIE Register here ➡️ app.evalandgo.com/f/325218/4qE... Full program 👇

Overview on published/presented data on MASH cirrhosis #LiverSky @bavenocoop.bsky.social 🖇️: authors.elsevier.com/sd/article/S...

🚨 Join us for the VALDIG PSVD Meeting – a 2-day event dedicated to PSVD! 🗓️ Dec 4–5, 2025 📍 CNAM, Paris 🇫🇷 💳 Onsite €150 (payment after reg.) | Online free 👉Organized by EURO-VALDIG NET & FILFOIE Register here ➡️ app.evalandgo.com/f/325218/4qE... Program 👇

🔎Around 1 in 4 people with CCA have chronic liver diseases, and 1 in 10 have cirrhosis. Read more here: ❇️ ow.ly/GIh450X2qc0

Our @GeorgKRAMER myself & @CristinaRIPOLL perspective on staging of #Decompensated #Cirrhosis - this was a Letter ✉️ to @jhepatology.bsky.social in response to an article by Dr. Verma @rajivjalan.bsky.social et al #NonAcuteDecompensation (NAD) 🔗 t.ly/mc4VG - who responded w/ an interesting proposal

In patients with provoked venous thromboembolism and ongoing risk factors, extended treatment with low-dose apixaban for 12 months resulted in a lower risk of recurrent VTE than placebo, with a low risk of major bleeding. Full HI-PRO trial results and Research Summary: nej.md/4p6tIDo

New online! Interaction of inflammation and portal hypertension in cirrhosis progression

If you are interested in portal hypertension and like to hear from all disciplines involved, this is the conference for you 👇🏼 Thank you for the invitation and the opportunity to review HRS-AKI and ascites management. #liversky @portal360mtg.bsky.social @bavenocoop.bsky.social

🚨 Mark your calendars! Baveno VIII Meeting → 27–28 March 2026 Reminder from @crisripoll.bsky.social, Baveno Vice-Secretary at #DGVS ⏳ only 6 months left! Register 👉 bavenocoop.net

@bavenocoop.bsky.social visiting the Japanese Society of Portal Hypertension 👀 at our auditorium 🙏 incredible hospitality 👉 See our 🇯🇵 friends at Baveno VIII

The passing of Prof. Jaume Bosch (1947–2025) has generated, and continues to generate, heartfelt tributes Here you can read some of them: Scientific societies 🇪🇺EASL: journal-of-hepatology.eu/action/showP... 🇪🇸AEEH: aeeh.es/obituario-ja... 🇨🇭SASL: sasl.unibas.ch/files/mixed%...

🔗 Full paper: doi.org/10.1111/apt.... 📝 Editorial by @reibergerthomas.bsky.social and Benedikt Simbrunner: onlinelibrary.wiley.com/doi/epdf/10.... #LiverTwitter

Some evidence on role of Simvastatin and Carvedilol in patients after variceal🩸. Stage of cirrhosis and right combination may b the 🔑 for statins in PHTN #LiverSky. @easlnews.bsky.social @bavenocoop.bsky.social @amcollegegastro.bsky.social @aasldnews.bsky.social journals.lww.com/ajg/abstract...

Editor's Essential Reading ➡️ A review of the diagnosis and management of hemochrojmatosis, a genetic iron overload disease that is under diagnosed and treatable Learn more: ow.ly/NIl350WuZoz

CIRROXABAN Study is finally here! 🔬 First DB RCT evaluating rivaroxaban in cirrhosis 💡 Complication-free survival benefit in moderate liver dysfunction—Child‑Pugh B7 (HR 0.26 [95 % CI 0.07–0.90]). ⚠️ Mild bleeding ↑, but no increase in severe events. 📄 www.journal-of-hepatology.eu/article/S016...

Another piece of evidence about the role of anticoagulants in cirrhosis. Results of a multicenter effort. The cirroxaban study. @hospitalclinic.bsky.social @idibaps.bsky.social @jhepatology.bsky.social kwnsfk27.r.eu-west-1.awstrack.me/L0/https:%2F...

What are the latest and concrete recommendations for the clinical application of AI in hepatology?🤖 Read now this position paper from the EASL AI Task Force from @jhepatology.bsky.social: easl.eu/news/new-pub... #LiverSky

Fear of Biopsying...Liver Lesions 😀Nice review on evaluating L1-RADS 3 & 4 lesions: www.gastrojournal.org/article/S001... 🤔How fearful should we be of tumor seeding from biopsies? 👍Apparently much less frequent than we thought.. Reassuring #Gastrosky #Liversky

Jaume Bosch No one, and I mean no one, made more seminal contributions to the measurement, interpretation & clinical applications of HVPG, the prognostic impact of CSPH and its rx. Truly in the pantheon of all time greatest hepatologists and a kind, generous person on top. RIP #liversky

Chronic venous insufficiency is mainly due to venous hypertension, the cause of which can be structural or functional. Treatment is aimed at decreasing venous hypertension through conservative, nonprocedural management. Learn more in this December 2024 Clinical Practice article: nej.md/41Zd5Av